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Background: In developing countries, the study of cytomegalo-
virus (CMV) coinfection in HIV-infected patients remains neglected.
Quantitative CMV polymerase chain reaction (PCR) is the gold
standard diagnostic tool for analyzing serum CMV replication and for
predicting CMV disease. We estimated the prevalence of replicating
CMV in sera of newly diagnosed HIV-infected Cambodian patients
and examined its impact on mortality.
Methods: This cohort study was based on 2 highly active
antiretroviral therapy treatment programs in Cambodia between
2004 and 2007. Quantitative CMV PCR was performed on baseline
serum samples of 377 HIV-infected patients.
Results: The prevalence of serum CMV DNA was 55.2% (150
of 272) in patients with CD4
+ count ,100/mm
3. In multivariate
analysis, hemoglobin ,9 g/dL, CD4
+ count ,100/mm
3, and
Karnofsky index ,50 were independently associated with positive
serum CMV DNA at baseline. During a 3-year follow-up period,
CMV viral load $3.1 log10 copies per milliliter was signiﬁcantly
associated with death independently of CD4
+ count, other opportu-
nistic infections, and highly active antiretroviral therapy.
Conclusions: As in industrialized countries, serum CMV replica-
tion is highly prevalent among HIV-infected Cambodian patients and
is associated with increased mortality. This underscores the impor-
tance of diagnostic CMV infection by PCR in sera of HIV-infected
patients with CD4
+ count ,100/mm
3 and treating this opportunistic
infection to reduce its associated mortality.
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INTRODUCTION
Cytomegalovirus (CMV) disease is an opportunistic
infection in HIV-infected patients, resulting from reactivation
of latent infection in patients with advanced immunosuppression.
In resource-limited settings, the diagnosis and the treat-
ment of CMV disease are generally not available and CMV
disease remains neglected. In previous studies conducted in
industrialized countries, detectable CMV DNA by polymerase
chain reaction (PCR) in plasma
1,2 or in whole blood
3 was an
independent predictor of death even after adjusting for HIV
RNA level or CD4 cell count. In Spanish patients with
advanced HIV infection, CMV viremia was even the strongest
predictor of death.
4
In this study, we estimated the prevalence of serum
CMV DNA in a cohort of 377 newly diagnosed HIV-infected
Cambodian patients. Serum CMV DNA was detected by the
use of a real-time qualitative and quantitative PCR technique.
Relations between CMV PCR qualitative and quantitative
results, clinical data, and patient survival were analyzed in
this cohort.
PATIENTS AND METHODS
Cohort Intake
This cohort was built within the highly active anti-
retroviral therapy (HAART) access program at Prea Bat
Norodom Sihanouk Hospital [program supported by Me ´decins
Sans Frontie `res (MSF), France] and Calmette Hospital
Received for publication August 22, 2008; accepted February 5, 2009.
From the *Unite ´ d’Epide ´miologie des Maladies Emergentes, Institut Pasteur,
Paris, France; †Laboratoire de Virologie, Universite ´ Rene ´ Descartes,
EA 36-20, Ho ˆpital Necker-Enfants Malades, Paris, France; ‡Unite ´ de
virologie, Institut Pasteur du Cambodge, Phnom Penh, Cambodia;
§Me ´decins Sans Frontie `res, Ho ˆpital Pre ´a Bath Norodom Sihanouk,
Phnom Penh, Cambodia;
kMe ´decins DuMonde, Ho ˆpital Kosamak, Phnom
Penh, Cambodia; {Epicentre, Paris, France; #Me ´decins Sans Frontie `res,
Paris, France; **Service des Maladies Infectieuses et Tropicales, Ho ˆpital
Calmette, Phnom Penh, Cambodia; and ††Universite ´ Rene ´ Descartes,
Service des Maladies Infectieuses et Tropicales, Centre d’Infectiologie
Necker–Pasteur, Ho ˆpital Necker–Enfants Malades, Paris, France.
This project has been funded by SIDACTION–Ensemble Contre Le SIDA.
Findings have been presented in part at the 48th Interscience Conference on
Antimicrobial Agents and Chemotherapy, October 25–28, 2008,
Washington, DC [abstract H-2336].
Correspondence to: Romain Micol, MD, MPH, Unite ´ d’Epide ´miologie des
Maladies Emergentes, Institut Pasteur, 28 rue du Docteur Roux, 75015
Paris, France (e-mail: romain.micol@gmail.com).
Copyright  2009 by Lippincott Williams & Wilkins
486 | www.jaids.com J Acquir Immune Deﬁc Syndr   Volume 51, Number 4, August 1, 2009(program supported by Me ´decins Du Monde, France), Phnom
Penh, Cambodia. It was based on the follow-up of HIV-
infected patients initially enrolled in a study of opportunistic
infections and more speciﬁcally assessing the clinical utility of
serum cryptococcal polysaccharide (CPS) for the diagnosis of
cryptococcal infection.
5 Between April and November 2004,
all HAART-naive HIV-infected adult patients seen for the ﬁrst
time as inpatients or outpatients were invited to participate
in the study. After signing an informed consent, patients
answered a questionnaire on sociodemographic characteristics
and medical history and were subjected to an in-depth clinical
examination. Investigations included a cerebrospinal ﬂuid
(CSF) examination for patients with symptoms suggestive of
meningoencephalitis and a chest x-ray for patients with
respiratory symptoms. A blood sample was taken for CD4 cell
count (CD4 count), serum CPS detection, and other analyses
(see laboratory examinations). Details of the study have been
reported elsewhere.
5
Cohort Follow-Up
In 2007, after investigations showing high prevalence of
CMV retinitis among patients with CD4 counts ,50/mm
3 in
several MSF HAART programs,
15 we decided to perform
a retrospective analysis of the serum samples collected in 2004
in Phnom Penh for the detection of CMV DNA. We also
reviewed the databases of the 2 treatment programs to deter-
mine the outcome (dead/alive/lost to follow-up) of the 377
HAART-naive HIV-infected adults screened in the initial
study. An active procedure was conducted between February
and April 2007 to trace patients lost to follow-up. At the time
of assessment, 9.4% (35 of 377) patients could not be traced
because of lack of proper identiﬁcation. Of the 342 remaining
patients, 100 (29.2%) were dead, 119 (34.8%) were still alive,
and 123 (36.0%) were lost to follow-up (ie, were late by more
than 3 months for their last scheduled visit).
Laboratory Analysis
During the 2004 survey, all patients provided a 10-mL
blood sample that was transported the same day to the
Institut Pasteur of Cambodia for CD4 count (FACScount;
Becton Dickinson, Franklin Lakes, NJ), serum CPS detection
(CALAS; Meridian Bioscience Europe, Nice, France), and
storage at 220C. Cryptococcal infection was deﬁned by
a positive CPS agglutination test (in serum or CSF) or positive
Cryptococcus neoformans culture (in blood, CSF or urine) or
positive india ink direct examination of CSF as described
previously.
6
In 2007, stored sera were used for CMV DNA detection
by PCR. DNA was extracted from 200 mL of serum with the
MagNA Pure Compact (Roche, Osterode am Herz, Germany)
following the MagNA Pure Compact Nucleic Acid Isolation
Kit I protocol. Extracted DNA was eluted in 100 mL of the
elution buffer provided by the manufacturer. The CMV real-
time PCR was conducted according to the protocol used since
2001 in the Virology Laboratory of Necker University
Hospital (Paris, France). This test is an in-house CMV real-
time PCR assay detecting a highly conserved region (74 base
pairs) of the CMV UL123.
7 PCR was performed in a 25 mL
volume containing 12.5 mL Platinum qPCR superMix-UDG
(Cat. No. 11730-025; Invitrogen, Cergy Pontoise, France),
400 nM of each primer, 200 nM of TaqMan probe (Applied
Biosystem, Courtaboeuf, France), and 5 mL of extracted DNA.
Reactions were performed on the iQ5 Real-Time PCR Detec-
tion System (Biorad, Hercules, CA). Quantiﬁcation was done
with serial dilutions (10
5 to 10 copies/PCR reaction) of a
prequantiﬁed plasmid containing the amplicon. Positive and
negative controls were added to each series. The sensitivity of
the CMV PCR test was 500 copies per milliliter (2.7 log10
copies/mL).
This initial study and its 2007 extension were approved
by the National Ethics Committee for Health Research of the
Cambodia Ministry of Health and by the Biomedical Research
Committee of Pasteur Institute.
Statistical Analyses
Continuous variables were presented with their median
and interquartile range (IQR). Variables were compared across
groups using the Mann–Whitney U test for continuous vari-
ables and the x
2 or Fischer exact test for categorical variables.
CD4 count categories were chosen based on thresholds
reﬂecting known levels of immunosuppression (#50, 51–100,
101–200, and .200/mm
3), whereas body mass index and
hemoglobin categories were based on quartiles.
Factors associated with serum CMV DNA detection
were identiﬁed using logistic regression. Variables with P val-
ues ,0.25 in univariate analysis were tested simultaneously
in the multivariate model and removed after a backward
stepwise procedure until all variables left in the model had
P values ,0.05. For multiple categorical variables, signiﬁ-
cance was tested using a maximum likelihood procedure.
Kaplan–Meier curves were used to estimate the survival
probability of patients according to their CMV DNA status at
inclusion in the cohort. A Cox model was used to estimate
hazard ratios associated with the mortality during the 3-year
follow-up. All variables introduced in the model were baseline
characteristics, except for HAART, which was treated as
a time-dependent variable (ie, patients contributed person-time
to the treated category only while under HAART). Patients
lost to follow-up were censored at the time they were lost
to follow-up.
For all analyses, statistical signiﬁcance was deﬁned as
P , 0.05. Statistical analyses were performed using SAS 8.02
(SAS Institute, Inc, Cary, NC).
RESULTS
Characteristics of the Patients
The baseline characteristics of the study population (N =
377) are summarized in Table 1. Approximately half of the
patients were male (50.9%) and were recruited through
inpatient (45.9%) or outpatient (54.1%) department. Median
(IQR) age was 35 (31–40) years. Patients were severely
immunosuppressed, as shown by low median (IQR) Karnofsky
index [70 (60–80)], body mass index [17.3 (15.6–19.3)
kg/m
2], and CD4 count [30 (9–120)/mm
3]. Most patients
presented clinical symptoms, 38.9% of them having tem-
perature $38.0C, 60.2% complaining of headache, and
52.1% diarrhea.
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Total (N = 377), n (%) Positive CMV PCR (n = 160), n (%) OR (95% CI) P
Type of service*
Inpatients 172 (45.9) 106 (61.6) 4.6 (3.0 to 7.1) 10
24
Outpatients 204 (54.1) 53 (26.0) 1
Age class in years
,29 67 (17.8) 28 (41.8) 1.2 (0.6 to 2.3) NS
29–39 211 (56.0) 95 (45.0) 1.4 (0.8 to 2.2)
.39 99 (26.2) 37 (37.4) 1
Sex
Male 192 (50.9) 96 (50.0) 1.9 (1.3 to 2.9) 0.003
Female 185 (49.1) 64 (34.6) 1
Karnofsky index†
#50 66 (17.6) 47 (71.2) 4.4 (2.5 to 7.9) ,10
24
.50 309 (82.4) 111 (35.9) 1
Body mass index
#15.6 93 (24.7) 56 (60.2) 5.0 (2.6 to 9.3) ,10
24
15.6–17.3 94 (25.0) 45 (47.9) 3.0 (1.6 to 5.6)
17.3–19.3 95 (25.3) 36 (37.9) 2.0 (1.1 to 3.8)
.19.3 94 (25.0) 22 (23.4) 1
Clinical signs
Temperature (C)
$38.0 146 (38.9) 79 (54.1) 2.2 (1.5 to 3.4) 0.0002
,38.0 229 (61.1) 79 (34.5) 1
Diarrhea
Presence 196 (52.1) 83 (42.4) 1.0 (0.7 to 1.5) NS
Absence 180 (47.9) 77 (42.8) 1
Headache
Presence 227 (60.2) 79 (34.8) 0.5 (0.3 to 0.7) 0.0002
Absence 150 (39.8) 81 (54.0) 1
Neck stiffness
Presence 32 (8.5) 17 (53.1) 1.6 (0.8 to 3.3) NS
Absence 345 (91.5) 143 (41.4) 1
Severe neurological signs
Presence 18 (4.8) 10 (55.6) 1.7 (0.7 to 4.5) NS
Absence 359 (95.2) 150 (41.8) 1
Associated opportunistic infections
Cryptococcal infection
Presence 58 (15.4) 31 (53.5) 1.7 (1.0 to 3.0) 0.07
Absence 319 (84.6) 129 (40.4) 1
Tuberculosis
Pulmonary 32 (8.5) 18 (56.3) 2.2 (1.1 to 4.6) 0.001
Extrapulmonary 70 (18.6) 41 (58.6) 2.4 (1.4 to 4.2)
Absence 275 (72.9) 101 (36.7) 1
Pneumocystosis
Presence 8 (2.1) 6 (75.0) 4.3 (0.7 to 31.1) 0.06
Absence 369 (87.9) 152 (41.2) —
Blood tests
CD4 cell count/mm
3
#50 224 (59.4) 133 (59.4) 29.2 (8.9 to 96.1) ,10
24
51–100 48 (12.7) 17 (35.4) 11.0 (3.0 to 40.3)
101–200 42 (11.2) 7 (16.7) 4.0 (1.0 to 16.5)
.200 63 (16.7) 3 (4.8) 1
488 | www.jaids.com q 2009 Lippincott Williams & Wilkins
Micol et al J Acquir Immune Deﬁc Syndr   Volume 51, Number 4, August 1, 2009Presence of Serum CMV DNA
CMV DNA was present in the serum of 42.4% (160 of
377) patients. As shown in Table 1, prevalence was higher in
febrile patients when compared with others (54.1% ver-
sus 34.5%, P = 0.0002), in patients with opportunistic
infections (tuberculosis, cryptococcal infection, and pneumo-
cystosis with borderline signiﬁcance for the latter two), and in
patients with higher levels of immunodepression. In particular,
CMV DNA was present in 59.4% (224 of 377) patients with
CD4 count #50/mm
3 and only in 4.8% in patients with CD4
count .200/mm
3. Of interest, CMV DNA presence was also
strongly associated with anemia, that is, being higher among
patients with lower hemoglobin levels. This association
remained in multivariate analysis, where Karnofsky index,
CD4 count, and hemoglobin level were all independently
associated with positive CMV DNA detection (Table 2).
The median (IQR) CMV viral load was 3.6 (3.1–4.2)
log10 copies per milliliter. Median (IQR) CMV viral load was
higher in patients with CD4 count #50/mm
3 when compared
with .50/mm
3: 3.7 (3.1–4.3) log10 copies per milliliter versus
3.4 (2.9–3.7) log10copies per milliliter,respectively(Wilcoxon
test, P = 0.01).
Mortality
Figure 1 displays the survival curves according to serum
CMV DNA presence. Patientswith positive serum CMV DNA
at baseline had higher mortality when compared with others
(log-rank test, P , 10
24). For patients with a negative CMV
DNA, the Kaplan–Meier death rate was 9.6% at 6 months,
17.3% at 12 months, and 25.3% at 24 months. For patients
with positive serum CMV DNA, these rates rose to 24.8%,
35.6%, and 53.62%, respectively. The hazard ratio [95%
conﬁdence interval (CI)] associated with serum CMV DNA
was 2.7 (1.8 to 4.0, P , 10
24). In an analysis restricted to the
group of patients with CD4 count #50/mm
3, the presence of
serum CMV DNA was still associated with death [log-rank
test, P = 0.005; hazard ratio (95% CI), 2.0 (1.2 to 3.4)
P = 0.006].
In multivariate analysis (Table 3), factors associated with
death were low baseline CD4 count, cryptococcal infection at
admission, and high baseline CMV DNA load. The CMV
DNA load was associated with increased risk of death only for
values higher than 3.1 log copies per milliliter. Compared with
patients with undetectable CMV DNA load, the hazard ratio
(95% CI) of death was 2.0 (1.1 to 3.8) for those with viral load
between 3.1 and 3.5 and was 3.6 (2.0 to 6.8) for those with
viral load higher $4.2 log copies per milliliter.
DISCUSSION
This is the ﬁrst study evaluating the burden of CMV
infection by real-time PCR in HIV-infected patients in
a developing country. The prevalence of serum CMV DNA
was very high, reaching 59.4% (133 of 224) among patients
with CD4 count #50/mm
3 and of the same magnitude (28%–
45%) as that reported in industrialized countries before the era
of HAART for patients with ,100 CD4/mm
3 count.
1,8 This
high prevalence is in accordance with the 93.3% prevalence of
anti-CMV total antibodies found in the sera of 359 blood
donors in a neighboring country, Thailand.
9 This study being
retrospective, routine retinal examinations were not performed
and the prevalence of CMV-related disease in our population
was not documented. However, a positive CMV PCR result
has been reported to be a strong predictor of CMV disease in
different studies conducted before and after HAART.
2,8,10,11
The present study showed that in a developing country,
a positiveCMV PCR in serum is a strong predictor of death for
TABLE 1. (continued) Characteristics of 377 HIV-Infected Patients According to Results of CMV PCR
Total (N = 377), n (%) Positive CMV PCR (n = 160), n (%) OR (95% CI) P
Hemoglobin (g/dL)‡
#9.0 115 (31.6) 74 (64.3) 5.7 (2.9 to 11.2) ,10
24
9.0–10.6 68 (18.7) 30 (44.1) 3.9 (2.2 to 6.7)
10.6–12.0 110 (30.2) 35 (31.8) 2.3 (1.2 to 4.2)
.12.0 71 (19.5) 17 (23.9) —
Percentage in the positive CMV PCR column is calculated for each line.
NS, not signiﬁcant; OR, odds ratio.
*n = 376.
†n = 375.
‡n = 364.
TABLE 2. Multivariate Analysis ofRisk Factors Associated With
Positive CMV PCR in 364 HIV-Infected Patients
Adjusted Odds Ratio (95% CI) P
Karnofsky index
#50 2.6 (1.4 to 4.9) 0.003
.50 1
CD4 cell count/mm
3
#50 17.9 (5.3 to 60.2) ,10
24
51–100 7.0 (1.8 to 27.0)
101–200 2.8 (0.6 to 12.3)
.200 1
Hemoglobin (g/dL)*
#9 3.8 (1.8 to 7.9) 0.0006
9–10.6 2.0 (0.9 to 4.5)
10.6–12.0 1.6 (0.7 to 3.5)
.12.0 1
*Missing value of hemoglobin level for 13 patients.
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count, HAART, and cryptococcal infection, highly prevalent
in this area.
This study adds to existing knowledge by showing that
increased mortality was observed only above a speciﬁc
threshold of CMV viral load, in this case 3.1 log10 copies per
milliliter (Table 3). In a previous study, it was reported that
each log10 increase in baseline CMV DNA load in plasma was
associated with a 2.2-fold increase in mortality.
1 Here, the
identiﬁcation of a threshold value could help to detect patients
at higher risk of mortality.
As shown elsewhere,
12 low hemoglobin levels were
strongly associated with a positive CMV PCR [odds ratio
(95% CI) = 3.8 (1.8 to 7.9)] when comparing patients with
hemoglobin #9t o.12 g/dL. It may be speculated that anemia
could simply be a marker of advanced immunosuppression
and thus of higher risk of CMV viremia. However, the
association remained in multivariate analysis, independentlyof
CD4 cell count, thereby suggesting that anemia may indeed
be a consequence of CMV viremia, a fact which has been
documented earlier either as inhibition of erythropoiesis
13 or
as hemolytic anemia.
14
We agree with Heiden et al
15 that CMV-related
pathogenesis is a neglected component of the AIDS epidemic
in developing countries. Until speciﬁc diagnosis and treatment
of CMV disease are available, some of the newly diagnosed
HIV-infected Cambodian patients will continue to die of CMV
infection before starting HAART and others will rapidly
develop CMV retinitis, which might lead to blindness either
before starting HAART or as a result of immune recovery
uveitis under HAART treatment.
16–18 In resource-limited
countries like Cambodia, it should be a priority to facilitate
and improve the diagnosis of retinitis by indirect ophtalmo-
scopy in all HIV-infected patients with CD4 count ,100/mm
3.
In laboratories equipped with PCR facilities, detection of
CMV DNA may also be of value to detect patients at high risk
of CMV disease. Finally, intravenous infusion of ganciclovir
or oral valganciclovir associated with intraocular injection of
ganciclovir should be made available for treatment of CMV
disease in HIV-infected patients of the developing world.
15,19,20
ACKNOWLEDGMENTS
The authors thank Yoann Madec for statistical advices
and Dr. Phillip Markham and Thomas Vancott for their time
and expertise in reviewing the article. Authors Contributions:
The contribution of all authors was essential. Duong Veasna,
Julie Galimand, Romain Micol, Philippe Buchy,and Marianne
Leruez-Ville have coordinated the PCR transfer from Necker
Hospital to Institut Pasteur du Cambodge; they performed the
CMV PCRs for this study and were responsible for the quality
FIGURE 1. Survival of 342 patients
according to serum CMV PCR at
baseline. Among 377 patients, 35
patients could not be traced. Log-
rank test ,10
24.
TABLE 3. Univariate and Multivariate Analysis of the
Mortality Risk Factors (Cox Model) in HIV-Infected Patients
(n = 340)
Hazard Ratio (95% CI)
Univariate Multivariate
HAART
Presence 0.55 (0.29 to 1.05) 0.36 (0.18 to 0.71)
Absence 1 1
CD4
+count/mm
3*
#50 2.3 (1.5 to 3.5) 3.0 (1.3 to 7.1)
51–200 0.8 (0.5 to 1.2) 2.6 (1.1 to 6.2)
.200 1 1
Cryptococcal infection
Presence 2.3 (1.4 to 3.7) 2.1 (1.3 to 3.5)
Absence 1 1
CMV PCR (log10 copies/mL)*
0–2.6 1 1
2.7–3.0 1.2 (0.6 to 2.1) 1.4 (0.7 to 2.8)
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